Manipal Hospitals
| Índia | Turquia | Áustria | |
| Tratamento complexo do neuroblastoma | de $24,500 | de $28,000 | de $180,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Neuroblastoma. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Neuroblastoma e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Neuroblastoma.
A Dra. Shruti Kate é especialista em tumores pediátricos, incluindo neuroblastoma, com formação no Tata Memorial Hospital – o principal centro de oncologia da Índia.
Especialista em hematologia-oncologia pediátrica, com foco em neuroblastoma nos Hospitais Artemis.
Top-tier private hospitals in India provide care comparable to Western standards through JCI-accredited facilities and advanced technology. Leading centers utilize robotic surgery and next-generation imaging protocols. Specialized clinics offer complex neuroblastoma care and CAR NK cell therapy. Treatment access is almost immediate without typical Western wait times.
Bookimed Expert Insight: While India ranks 5th globally for medical requests, the true value lies in specialized oncology clusters. Clinics like Fortis Gurgaon and Global Hospital Chennai offer a massive bed capacity across 40+ departments. This volume ensures that pediatric oncologists see more rare cases like neuroblastoma in a month than many Western consultants see in a year. When choosing, prioritize clinics with a dedicated pediatric oncology team rather than general surgical centers.
Patient Consensus: Patients note that private centers in major cities feel world-class and offer faster access to senior consultants. They emphasize choosing high-volume hospitals to ensure the facility has enough pediatric ICU backup and specialized anesthesia experience.
Success rates for neuroblastoma treatment in India reach 95% to 100% for low-risk cases. Intermediate-risk groups show 80% to 90% five-year survival. High-risk metastatic cases remain challenging with rates between 24% and 52.5%. Specialist tertiary centers report up to 81.6% survival for high-risk patients.
Bookimed Expert Insight: Data suggests specialized oncology centers like HCG Manavata or Fortis Gurgaon offer a significant advantage over general hospitals. Fragmented care, where chemotherapy starts at smaller clinics before transferring, can drop survival rates to 41.1%. Choosing a multidisciplinary facility with pediatric transplant capabilities ensures the consistent protocol necessary for high-risk cases.
Patient Consensus: Patients emphasize that success depends heavily on risk classification rather than just the facility name. They recommend asking doctors specifically about survival ranges for your child's exact risk group and stage.
Neuroblastoma treatment in India follows international risk-stratification protocols involving surgery, chemotherapy, and radiation. Major oncology centers in Delhi and Bengaluru provide advanced therapies. These include autologous stem cell transplants and radiopharmaceuticals like high-dose MIBG therapy for high-risk patients.
Bookimed Expert Insight: Quality indicators for neuroblastoma care in India are linked to clinic volume and accreditation. Facilities like Manipal Hospitals and Global Hospital Chennai serve over 2,000,000 patients annually. This high volume typically correlates with more robust pediatric transplant infrastructure. Always check if a center holds NABH or JCI accreditation. These certifications ensure the facility meets international safety standards for complex pediatric oncology cases.
Patient Consensus: Families emphasize that treatment plans must be customized based on risk group and stage. Many note it is important to confirm if a hospital has dedicated pediatric oncology and transplant expertise before starting aggressive protocols.
Advanced targeted therapies and immunotherapies are available in India at major oncology centers. These facilities offer immune checkpoint inhibitors like Pembrolizumab and indigenous CAR T-cell therapies. Precision medicine is supported by JCI-accredited labs performing molecular profiling for specific genetic mutations in neuroblastoma cases.
Bookimed Expert Insight: India has become a global leader in specialized oncology by developing affordable homegrown therapies. While Western CAR T-cell treatments cost over $400,000, Indian alternatives like NexCAR19 are available for around $36,000 to $72,000. Large networks like Manipal Hospitals serve 2,000,000 patients annually, demonstrating the massive infrastructure available for high-volume care.
Patient Consensus: Patients note that while advanced drugs exist, they are often concentrated in major tertiary centers. Families emphasize the need to specifically request molecular profiling to access these newer targeted options.
Neuroblastoma treatment in India typically spans 6 to 12 months for high-risk cases. This comprehensive process involves several phases. These include induction chemotherapy, surgical resection, and consolidation therapy. Some protocols also require stem-cell transplants and maintenance immunotherapy to ensure long-term success.
Bookimed Expert Insight: Indian oncology centers like HCG Manavata Cancer Centre specialize in integrated care with over 40 consultant oncologists. Our data shows that choosing large, JCI-accredited hubs like BLK Super Speciality Hospital often centralizes diagnostics and surgery. This consolidation can save families 2 to 3 weeks otherwise spent on external referrals.
Patient Consensus: Patients note that treatment timelines are rarely fixed. Success depends on recovery periods between cycles. Families emphasize the need for patience during unpredictable delays caused by low blood counts or minor infections.
Long-term neuroblastoma follow-up care involves lifelong surveillance for tumor recurrence and managing treatment-related late effects. Survivors require frequent clinical checkups Every 3 to 4 months. Care includes MIBG scans and catecholamine biomarker testing to monitor for relapse. Multi-specialty teams oversee growth, organ function, and secondary cancer screening.
Bookimed Expert Insight: Patients seeking neuroblastoma care in India benefit from massive institutional expertise. For example, Manipal Hospitals serves 2,000,000 patients annually across its network. This high volume allows centers to establish dedicated survivorship clinics. These clinics integrate pediatricians and oncologists like Dr. Shruti Kate to manage complex late effects. India's top hospitals often hold JCI or NABH accreditations. This ensures follow-up protocols meet the same rigorous safety standards as European facilities.
Major hubs for neuroblastoma treatment in India include Mumbai, Delhi NCR, Chennai, and Bengaluru. These cities provide multidisciplinary pediatric oncology centers and advanced bone marrow transplant units. Specialized facilities like Apollo Proton Cancer Centre offer precise technologies essential for treating intermediate and high-risk cases.
Bookimed Expert Insight: While overall hospital volume is high, neuroblastoma treatment costs significantly less in India than in Western countries. Complex protocols may cost approximately $24,500 to $52,000. Choosing clinics in cities like Bengaluru or Gurgaon offers access to surgeons with 30+ years of experience, such as those at Manipal Hospitals or Artemis Hospitals.
Patient Consensus: Families emphasize that coordinated pediatric oncology expertise is more important than general hospital brand. They often travel to major metro hubs for initial diagnosis while coordinating long-term follow-up closer to home.